NCT04580654View on ClinicalTrials.gov

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

May 7, 2021

Study Completion Date

May 7, 2021

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

CSL312

Fully human immunoglobulin G4/lambda recombinant monoclonal antibody against Factor XIIa

Trial Locations (1)

92801

Anaheim Clinical Trials, LLC, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors

lead

CSL Behring

INDUSTRY